Biopharmaceutical News and Research

RSS

Cerba Research is officially a member of Hong Kong Bio-Med Innotech Association (HKBMIA)

Cerba Research announces membership of HKBMIA to act as an advisor on speciality testing and routine clinical trials testing to advance research and health while supporting Asia pacific healthcare companies develop new therapeutics.

From Cerba Research 6 Jan 2023

Historic agreement to accelerate trials into vaccines for cancer and wider diseases

Trials into vaccines for cancer and wider diseases will accelerate after the government reached a historic agreement with a leading biopharmaceutical firm to bring revolutionary research to England.

5 Jan 2023

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments.

From PhoreMost 5 Jan 2023

PhoreMost and ThinkCyte collaborate to advance AI based drug discovery

PhoreMost Ltd. and ThinkCyte K.K today announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).

From PhoreMost 16 Dec 2022

Two Cents' Worth: Shared decision making in renal cell carcinoma (RCC)

In this interview, we speak to Steve Pointon, patient advocate in remission from RCC, and Dr Harm van Melick, Consultant Urologist, about their experiences with shared decision-making and the impact it can have on people living with renal cell carcinoma (RCC).

From Ipsen 15 Dec 2022

Multi-stage HIV vaccine regimen shows promising results in Phase 1 clinical trial

The George Washington University Vaccine Research Unit in partnership with Scripps Research, IAVI, Fred Hutchinson Cancer Center (FHCC) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases Vaccine Research Center published the results of their Phase 1 Clinical Trial in Science.

8 Dec 2022

Fujifilm Invests $188 Million in New Cell Culture Media Manufacturing Facility

FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA.

From FUJIFILM Corporation 22 Nov 2022

FDA approves first-ever type 1 diabetes delaying drug Tzield (teplizumab-mzwv)

On November 17, 2022, the US Food and Drug Administration (FDA) approved a pathbreaking new drug called Tzield. This injectable formulation contains a combination of two drugs that could push back the onset of type 1 diabetes (T1D) in adults at stage 3 and children aged eight years or more at stage 2.

20 Nov 2022

Behind the Scenes of the Oncology & Precision Medicine Conferences 2022

During the conference, we caught up with some of the speakers to learn more about their work, what they were presenting, and their thoughts about the future of Oncology and Precision Medicine.

15 Nov 2022

Experimental therapeutic cancer vaccine leads to significant tumor regression in mice

An experimental therapeutic cancer vaccine induced two distinct and desirable immune system responses that led to significant tumor regression in mice, report investigators from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

10 Nov 2022

Champalimaud Foundation researcher wins the Eppendorf & Science Prize for Neurobiology

The international Eppendorf & Science Prize for Neurobiology, which was established in 2002 and awards $25,000 annually to young scientists who have advanced our understanding of the brain and nervous system, has selected Ana Filipa Cardoso as a prize finalist.

3 Nov 2022

Study finds new drug combination to be more effective against complicated urinary tract infections

An international study led by a Rutgers scientist comparing new and older treatments against complicated urinary tract infections has found a new drug combination to be more effective, especially against stubborn, drug-resistant infections.

25 Oct 2022

Researchers identify specific T cell required to bolster vaccine immunity against fungal pneumonia

Researchers at the University of Illinois College of Veterinary Medicine have demonstrated in a mouse model that a specific type of T cell, one of the body's potent immune defenses, produces cytokines that are necessary for the body to acquire immunity against fungal pathogens.

25 Oct 2022

University of Tübingen, Boehringer Ingelheim launch AI and data science fellowship program

University of Tübingen, a leading member of Cyber Valley, Europe’s largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world. Three to five fellowships will be awarded per year for up to three years with a target of nine to fifteen fellows in the program after five years.

21 Oct 2022

Chinese study determines the real-world effectiveness of COVID-19 vaccines

A recent study aimed to determine the real-world effectiveness of COVID-19 vaccines against SARS-CoV-2 infection.

14 Oct 2022

Enterin and Parkinson's Virtual Biotech collaborate to study the effects of ENT-01 on PD-associated dementia

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases announces a collaboration with the Parkinson's Virtual Biotech, the drug development and discovery arm of Parkinson's UK.

13 Oct 2022

Sartorius releases the 6th edition of its popular live-cell analysis handbook

Sartorius, a leader in new technologies for real-time, live-cell imaging and analysis, has released the 6th edition of its popular Live-Cell Analysis Handbook.

From Sartorius 10 Oct 2022

New lab technique could spark a 'paradigm shift' in testing protein-based drugs

New Jersey Institute of Technology researchers have unveiled a new lab technique they say represents a "paradigm shift" in how pharmaceutical laboratories test and produce new protein-based drugs, such as therapeutic monoclonal antibodies being developed to treat a variety of diseases, from cancers to infectious diseases.

27 Sep 2022

New board members bring significant leadership experience in the biotech sector

Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, is pleased to announce the appointment of three new members to its Board of Directors: Dr. Nancy Krieger, Dr. Don Haut, and Dr. Devyn Smith.

From Aspect Biosystems 22 Sep 2022

ValitaCell joins Beckman Coulter Life Sciences

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, announces it has acquired ValitaCell Ltd., a biotechnology company that creates pioneering analytical products and technologies for the biopharmaceutical industry.

From Beckman Coulter Life Sciences 16 Sep 2022